Moderna, Inc. · NASDAQ:MRNA
Moderna — ESG Presentation (June 2021)
28 slides from Moderna's sustainability presentation, Jun 7, 2021
Slide 1: Commitment to Sustainability
Commitment to Sustainability Stéphane Bancel, CEO June 7, 2021
Slide 2: Forward-looking statements and Disclaimer
Forward-looking statements and Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the Company’s efforts to develop the Moderna COVID-19 Vaccine against SARS- CoV-2, a
Slide 3: Moderna COVID-19 Vaccine: Authorized Use & Important Safety Information
Moderna COVID-19 Vaccine: Authorized Use & Important Safety Information Authorized Use in the United States: The Moderna COVID-19 Vaccine has not been approved or licensed by the US Food and Drug Administration (FDA), but has been authorized for emergency use by FDA, under an Emergency Use Authoriza
Slide 4: Our mission
Our mission To deliver on the promise of mRNA science to create a new generation of transformative medicines for patients. Slide 4
Slide 5: Moderna's mission guided focus created the conditions for the success of our COVID-19 vaccine
Moderna’s mission guided focus created the conditions for the success of our COVID-19 vaccine Founded in 2010 to deliver on the promise of mRNA science to create a Expanding our best-in-class new generation of transformative mRNA vaccines and medicines for patients Nasdaq listing therapeutics pipeli
Slide 6: Moderna as of June 2021
Moderna as of June 2021 Phase 3 Phase 2 13 positive Phase 1 readouts Pipeline Commercial COVI D-19 v accine preparation PCV, OX40L, VEGF 9 I D v accine programs PCV, OX40L, VEGF, anti-Chikungunya antibody (repeat dose) CMV v accine Infectious Disease Vaccines mRNA Therapeutics Programs in developmen
Slide 7: Our mission is embedded in our business strategy and how we think about sustainability
Our mission is embedded in our business strategy and how we think about sustainability Key questions we ask ourselves as we think about how Moderna can impact the world: 1 How can we contribute to society in new and innovative ways that will positively affect global health? 2 Can our medicines help
Slide 8: Our Commitment to Responsibility
Our Commitment to Responsibility Commitment to Corporate Social Responsibility established two years ago as we were considering the impact we could have with our mRNA medicines in development Slide 8
Slide 9: Today's Focus Areas
Today’s Focus Areas Our steps to becoming a leader in biopharma sustainability 1 Medicines for Patients 2 Clinical Trial Practices 3 Human Capital Management Slide 9
Slide 10: Medicines for Patients
1 Medicines for Patients Today’s Focus Areas Moderna’s strategy since inception has been to have the greatest impact on human health COVID-19 vaccine: We will continue to develop variant booster shots until COVID-19 is under control Accelerating investments in prophylactic vaccines, including vaccin
Slide 11: 102 million doses delivered in 1Q 2021
Moderna’s COVID-19 vaccine is protecting people in 37 countries already 102 million doses of Moderna COVID-19 vaccine delivered in 1Q 2021 Slide 11
Slide 12: Our commitment to provide our COVID-19 vaccine across the globe
Our commitment to provide our COVID-19 vaccine across the globe North and South America Agreement with GAVI, the Vaccine Alliance to supply up to Signed APAs 500 million doses to the 92 GAVI COVAX Advance Market United States Commitment (AMC) low- and- middle income countries Canada Colombia E
Slide 13: 9 vaccine programs for major unmet needs
Largest first-in-class vaccine development pipeline in the industry 9 vaccine programs for major unmet needs Preclinical Program ID # development Phase 1 Phase 2 Phase 3 Commercial Moderna rights mRNA-1273 Worldwide COVID-19 v accine mRNA-1273.351/-211 mRNA-1283 mRNA-1273.351/-211 BARDA funded mRNA-
Slide 14: Public-Health Vaccines
Public-Health Vaccines In partnership with: Three development programs Vaccines against pathogens of • Zika (mRNA-1893) – Major public health concern are critical arthropod (mosquito) driven to health security epidemic in 2016; planning for Phase 2 • Nipah (mRNA-1215) – Outbreak potential with 40 to
Slide 15: We hope to make a similar impact with our mRNA medicines
We hope to make a similar impact with our mRNA medicines 5 oncology trials currently in the clinic 1 program ongoing in cardiovascular 2 autoimmune candidates 4 programs for rare diseases mRNA is a new class of medicines Slide 15
Slide 16: Today's Focus Areas
Today’s Focus Areas Our steps to becoming a leader in biopharma sustainability 1 Medicines for Patients 2 Clinical Trial Practices 3 Human Capital Management Slide 16
Slide 17: Clinical Trial Practices
2 Clinical Trial Practices Today’s Focus Areas Moderna is committed to increasing diversity in our clinical trials by identifying the barriers that currently impede inclusion, and implementing approaches to more efficiently identify, engage, recruit, and retain study participants from racial/ethnic
Slide 18: Slowed Phase 3 COVE trial enrollment to ensure representation of diverse and at-risk populations
Slowed Phase 3 COVE trial enrollment to ensure representation of diverse and at-risk populations Pivotal Announced a slowing Enrollment completed Phase 3 COVE of enrollment to ensure of Phase 3 study study begins the representation of ✓ Slowed enrollment in the communities of color COVE study to ens
Slide 19: The population in the COVE Study is representative of the US population at-risk for COVID-19 infection
The population in the COVE Study is representative of the US population at-risk for COVID-19 infection COVE Study All others Asian Black/AA Hispanic/Latinx White Participants Count White, non-Hispanic 19,060 3% Hispanic or Latinx 6,247 US population 6% 13% 18% 60% Black or African 3,114* 20201 Ameri
Slide 20: We are setting diversity targets for our Phase 3 CMV trial
We are setting diversity targets for our Phase 3 CMV trial – ~150 sites across the U.S., Europe and APAC – Pivotal Phase 3 trial will test the 100 μg dose level – Expected enrollment of ~8000 participants – Expected to start in 2021 CMV Trial Participants – US Demographic Composition Target White, n
Slide 21: Today's Focus Areas
Today’s Focus Areas Our steps to becoming a leader in biopharma sustainability 1 Access to Medicines 2 Clinical Trial Practices 3 Human Capital Management Slide 21
Slide 22: Human Capital Management
3 Human Capital Management Today’s Focus Areas Moderna’s Values – Established and integrated from day one Bold Collaborative Curious Relentless We accept responsibility for We know that the only way to We are intensely curious and We are tenacious in pursuit of deliv ering on the promise of accompli
Slide 23: Organizational Culture of Quality was leveraged in our COVID-19 Vaccine development
Organizational Culture of Quality was leveraged in our COVID- 19 Vaccine development • An effective and sustainable Quality Employee Empowerment Culture is: and Ownership • Characterized by employees who are Continual Communication, motivated to consistently strive for the highest Process Teamwork a
Slide 24: We are making steps to increase diversity & inclusion across the organization
We are making steps to increase diversity & inclusion across the organization 2018 2019 2020 % of workforce who are women 44% 46% 46% % of leadership (VP and 29% 35% 37% above) who are women % of workforce who are racially/ethnically diverse (U.S. 32% 32% 35% only) Slide 24
Slide 25: Employee benefit programs
Employee benefit programs Equitable benefits across the organization are fundamental to our culture Intellectual and Professional Growth Competitive Benefits • Moderna University • Generous paid time off and • Partnership with Harvard Medical parental leave, paid sabbaticals, School • All U.S. emplo
Slide 26: Commitment to the environment and community are key pillars of Moderna
Commitment to the environment and community are key pillars of Moderna Commitment to the Environment Community Outreach Aim to source U.S. facilities with In our communities, we are giving back in- renewable energy and offset carbon person and virtually—and thinking about emissions through Renewable
Slide 27: Board's role in the COVID-19 vaccine development and our strategic priorities for a sustainable future
Board’s role in the COVID-19 vaccine development and our strategic priorities for a sustainable future COVID-19 Vaccine Development Strategic Priorities that Promote a Sustainable Future Added directors with drug development and commercial experience before/early in the 1. Maximize the impact of the
Slide 28: Thank You!
“Se We've been at this for Le Weel, Our mRNA platform iS amodern approach to medicine. Thank You! But it’s just the beginning. moderna